AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)

Candel Therapeutics

Status and phase: Completed; Phase 1

Conditions: Pancreatic Adenocarcinoma; Pancreatic Cancer

Treatments: Drug: Valacyclovir; Biological: AdV-tk

Study type: Interventional

Funder types: Industry

Identifiers

NCT00638612

PaTK01

Details and patient eligibility

About

The purpose of this Phase 1 study is to evaluate the safety and potential efficacy of Gene Mediated Cytotoxic Immunotherapy for pancreatic cancer. The approach uses an adenoviral vector (disabled virus) engineered to express the Herpes thymidine kinase gene (AdV-tk), followed by an antiherpetic prodrug, valacyclovir.

Full description

The AdV-tk vector is injected into the tumor or tumor bed at the time of biopsy or standard tumor surgery after which valacyclovir pills are taken for 14 days. Two courses of AdV-tk, each followed by valacyclovir, are given as adjuvant to standard of care therapies (surgery and/or chemoradiation) which have been shown to work cooperatively with AdV-tk to kill tumor cells. Arm A is for resectable tumors in which the first course is given prior to surgery and the second is at the time of surgery. Arm B is for locally advanced disease in which both AdV-tk injections are administered by needle injection into the tumor before and during chemoradiation. The hypothesis is that this combination therapy can be safely delivered and will lead to improvement in the clinical outcome for patients with pancreatic cancer.

Enrollment: 27 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Must have presumed pancreatic adenocarcinoma based on clinical and radiologic evaluation with identifiable tumor accessible for injection (pathologic diagnosis of pancreatic adenocarcinoma must be made prior to AdV-tk injection
• For Arm A, resectable disease. Arm B for locally advanced disease has completed accrual.
• Performance status must be ECOG 0-2
• SGOT (AST)<3x upper limit of normal
• Serum creatinine<2mg/dl and calculated creatinine clearance >10ml/min
• Platelets>100,000/mm3 and WBC>3000/mm3 and ANC>1500/mm3
• Must give study specific informed consent prior to enrollment

Exclusion criteria

• Primary hepatic dysfunction including active hepatitis but not to exclude patients due to obstructive jaundice. If obstructive jaundice is clinically significant, bilirubin should be stable or decreasing prior to enrollment.
• Evidence of clinically significant pancreatitis as determined by the investigator.
• Patients on corticosteroids or other immunosuppressive drugs
• Known HIV+ patients
• Patients with acute infections (viral, bacterial or fungal infections requiring therapy)
• Pregnant or breast-feeding patients. Female patients of childbearing age must have negative serum or urine pregnancy test within 1 week of beginning therapy
• Evidence of distant metastatic disease at the time of enrollment or other malignancy (except squamous or basal cell skin cancers) and no prior abdominal radiation therapy or prior treatment for pancreatic cancer
• Other serious co-morbid illness or compromised organ function

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

27 participants in 2 patient groups

A resectable

Experimental group

Description:

Arm A is for resectable tumors. The first AdV-tk course is given prior to surgery by CT or EUS guided injection into the tumor followed by 14 days of valacyclovir. The second AdV-tk injection is into the tumor bed at the time of surgery again followed by 14 days of valacyclovir.

Treatment:

Biological: AdV-tk

Drug: Valacyclovir

B locally advanced

Experimental group

Description:

Arm B is for locally advanced tumors for which chemoradiation is the planned standard of care treatment. AdV-tk is delivered by CT or EUS guided injection into the tumor. The first AdV-tk injection is given prior to starting chemoradiation and the second in week 3 of chemoradiation. Both injections are followed by 14 days of valacyclovir. Enrollment has been completed for Arm B.

Treatment:

Biological: AdV-tk

Drug: Valacyclovir